Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Fetal Programming and Environmental Exposures: Implications for Prenatal Care and Pre-Term Birth

Fetal Programming and Environmental Exposures: Implications for Prenatal Care and Pre-Term Birth

Monday, June 11, 2012 - Tuesday, June 12, 2012

The New York Academy of Sciences

Presented By

Presented by the New York Academy of Sciences and Cincinnati Children's Hospital Medical Center

 

Over the past two decades, it has been increasingly recognized that prenatal environmental and pharmaceutical exposures can adversely influence fetal programming, which plays a role in pre-term birth and is linked to lasting adverse health effects and the risk of adult health disorders such as diabetes, high blood pressure, and cardiovascular disease. The New York Academy of Sciences (NYAS) and Cincinnati Children's Hospital Medical Center are jointly presenting a 1.5-day scientific symposium to explore recent discoveries, challenges, and future research directions that further our understanding of the complex environmental and genetic factors, and gene–gene as well as gene–environment interactions responsible for fetal programming in utero and pre-term birth.

This conference will provide a neutral forum for discussion to multidisciplinary science investigators such as toxicologists, obstetricians, neonatologists, pediatricians, endocrinologists, epidemiologists, public health and regulatory experts from basic research to clinical settings, including experts in embryonic, fetal, and childhood development, reproductive medicine and biology, and environmental toxicology. Conference attendees will explore the impact of genetic, epigenetic, and environmental factors on the stages of prenatal development, including pre-implantation, implantation, decidualization, placentation, fetal programming in utero, and links to pre-term birth and other pregnancy disorders.

Experts with diverse perspectives will engage in a dialogue about possible ways in which we can better predict, assess, and decrease the effects of environmental and genetic factors that predispose to adverse fetal outcomes and pre-term birth, thus lowering the enormous associated physical, psychological, and economic costs.

Registration Pricing

 By 4/20/2012After 4/20/2012Onsite: 6/11/2012
Member$200$250$275
Student / Postdoc / Fellow Member$125$175$200
Nonmember Academic$250$300$325
Nonmember Corporate$300$350$375
Nonmember Not for Profit$250$300$325
Student / Postdoc / Fellow Nonmember$125$175$200

 

Presented by

For a full list of sponsors, please view the Sponsors tab.

Agenda

* Presentation times are subject to change.


Day 1 — Monday, June 11, 2012

11:00 AM

Registration & Poster Set-up

11:00 AM

Meet & Greet Networking Session (concurrent)
Light refreshments available

12:00 PM

Opening Remarks
Brooke Grindlinger, PhD, The New York Academy of Sciences
Jeffrey A. Whitsett, MD, Cincinnati Children's Hospital Medical Center

12:15 PM

Keynote Address
Challenges for Reproductive Toxicology Posed By Unpredicted Effects on Fetuses Of Very Low-Doses Of Estrogenic Endocrine Disrupting Chemicals
Frederick S. vom Saal, PhD, University of Missouri–Columbia

Session I: Genetic / Epigenetic Programming of Pre-implantation Development

Chair: Marco Conti, MD, University of California, San Francisco
 

12:45 PM

Networks of RNA Binding Proteins Regulate Maternal mRNA Translation Essential for Oocyte Maturation and Early Embryo Development
Marco Conti, MD, University of California, San Francisco

1:10 PM

Maternal Diabesity, Oocyte Quality and Reproductive Outcomes
Kelle H. Moley, MD, Washington University in St. Louis School of Medicine

1:35 PM

Trophoblast Cell Subtypes Orchestrating the Development of the Maternal-Fetal Interface
James Charles Cross, DVM, PhD, University of Calgary

2:00 PM

Session I Panel and Audience Discussion

2:20 PM

Networking Break

Session II: Embryo–Uterine Cross-Talk

Chair: Adrian Erlebacher, MD, PhD, New York University Langone Medical Center
 

2:50 PM

Paracrine Signals Regulating Embryo Implantation and Uterine Decidualization
Francesco J. DeMayo, PhD, Baylor College of Medicine

3:15 PM

Nuclear Receptor Regulation of Gestation
Bruce Murphy, PhD, Université de Montréal

3:40 PM

Immune Surveillance of the Maternal/Fetal Interface: Implications for Fetal Loss and Preterm Birth
Adrian Erlebacher, MD, PhD, New York University Langone Medical Center

4:05 PM

Session II Panel and Audience Discussion

Session III: Young Investigator Presentations

Chair: Sudhansu K. Dey, PhD, Cincinnati Children's Hospital Medical Center
 

4:25 PM

Asynchronous Peri-Implantation Events Characterize a Mouse Model of Preeclampsia, BPH/5
Jenny Sones, DVM, Cornell University

4:40 PM

Heightened Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling Provokes Premature Decidual Senescence and Preterm Birth
Jeeyeon Cha, Cincinnati Children's Hospital Medical Center

4:55 PM

Extraembryonic Hematopoietic Niches: Cross-Talk between Non-Hematopoietic and Hematopoietic Populations in Human Placenta and Chorion
Alicia Bárcena, PhD, University of California, San Francisco

5:10 PM

Effects of Bisphenol A Exposure on Genomic Imprinting in Mouse
Martha Susiarjo, PhD, University of Pennsylvania

5:25 PM

Networking Reception and Poster Session

7:00 PM

Day 1 Concludes

Day 2 — Tuesday, June 12, 2012

8:00 AM

Networking Breakfast

8:00 AM

Young Investigators Career Mentoring Breakfast (concurrent)
Editor's Guide to Writing and Publishing Your Paper
Brooke Grindlinger, PhD, The New York Academy of Sciences

Session IV: Decidualization and Placentation

Chair: R. Michael Roberts, PhD, University of Missouri–Columbia
 

8:45 AM

Fate Specification During Human Pre-Implantation Development
Susan J. Fisher, PhD, University of California, San Francisco

9:10 AM

Regulatory Pathways Controlling Hemochorial Placentation
Michael J. Soares, PhD, Kansas University Medical Center

9:35 AM

Conversion of Umbilical Cord Mesenchyme to Trophoblast: A Glimpse at the Past
R. Michael Roberts, PhD, University of Missouri–Columbia

10:00 AM

Session IV Panel and Audience Discussion

10:20 AM

Networking Break

10:50 AM

Keynote Address
Epigenetics, Imprinting, and the Fetal Origins of Disease Susceptibility
Randy L. Jirtle, PhD, Duke University

Session V: Genetic and Environmental Influences Affecting Fetal Programming In Utero

Chair: Sarah F. Leibowitz, PhD, The Rockefeller University
 

11:15 AM

Glucose Tolerance in Adults after Prenatal Exposure to Famine
John R. G. Challis, PhD, University of Toronto

11:40 AM

Paternal Influence on Offspring Metabolism
Oliver J. Rando, MD, PhD, University of Massachusetts Medical School

12:05 PM

Role for Placental Metabolic Pathways in Modulating Fetal Brain Development: Impact of Serotonin
Pat R. Levitt, PhD, University of Southern California

12:30 PM

Lunchtime Breakout Roundtable Discussions
Conference faculty will lead informal, intimate breakout roundtable discussions during the lunch period. A robust dialogue among all attendees will be encouraged and shaped by the use of predetermined discussion questions. Summaries of major themes emerging from the discussions will be presented in the concluding Panel and General Audience Discussion.

Session V: Genetic and Environmental Influences Affecting Fetal Programming In Utero (continued)

Chair: Sarah F. Leibowitz, PhD, The Rockefeller University
 

1:30 PM

Mechanisms of Genetic Quality Control in the Germline
John Schimenti, PhD, Cornell University

1:55 PM

Maternal High-Fat Diet, Alcohol and Fetal Programming
Sarah F. Leibowitz, PhD, The Rockefeller University

2:20 PM

Session V Panel and Audience Discussion

2:50 PM

Networking Break

Session VI: Pregnancy Disorders and Prematurity: Gene–Environment Interactions

Chair: S. Anath Karumanchi, MD, Beth Israel Deaconess Medical Center
 

3:15 PM

Genetics and Genomics of Human Preterm Birth
Louis J. Muglia, MD, PhD, Cincinnati Children's Hospital Medical Center

3:40 PM

The Rebirth of Progesterone: Cervical Ultrasound and Progesterone to Prevent Preterm Birth
Roberto Romero, MD, National Institute of Child Health & Human Development, NIH

4:05 PM

Angiogenesis and Preeclampsia: Functional Characterization of Two Novel Secreted Gene Products Of Placental Origin (Sflt1 And Seng)
S. Anath Karumanchi, MD, Beth Israel Deaconess Medical Center

Session VII: Environment, Hormone Action, and Pharmacological / Endocrine Disruptors

Chair: L. David Wise, PhD, Merck
 

4:30 PM

Disruption of Uterine Cytodifferentation by Developmental Exposures to Diethylstilbrestrol
Liang Ma, PhD, Washington University in St. Louis School of Medicine

4:55 PM

Making Eggs and Sperm: Environmental Effects on Gametogenesis
Patricia Hunt, PhD, Washington State University

5:20 PM

Prenatal Development Toxicity Study Design for Pharmaceucticals
L. David Wise, PhD, Merck

5:45 PM

Session VI & VII Panel and General Audience Discussion
How Can We Better Predict, Assess, and Lower the Risk of and/or Prevent Environmental and Genetic Factors that Predispose to Adverse Fetal Outcomes and Pre-term Birth?
 
Panelists
Patricia Hunt, PhD, Washington State University
Liang Ma, PhD, Washington University in St. Louis School of Medicine
Margaret Ann Miller, PhD, National Center for Toxicological Research, US Food and Drug Administration
Louis J. Muglia, MD, PhD, Cincinnati Children's Hospital Medical Center
John M. Rogers, PhD, United States Environmental Protection Agency
Thaddeus Schug, PhD, National Institute of Environmental Health Sciences
Frederick S. vom Saal, PhD, University of Missouri–Columbia
L. David Wise, PhD, Merck

6:25 PM

Closing Remarks
Susan J. Fisher, PhD, University of California, San Francisco

6:30 PM

Conference Concludes

Speakers

Organizers

Sudhansu K. Dey, PhD

Cincinnati Children's Hospital Medical Center

Susan J. Fisher, PhD

University of California, San Francisco

Jeffrey A. Whitsett, MD

Cincinnati Children's Hospital Medical Center

Keynote Speakers

Randy L. Jirtle, PhD

Duke University

Frederick S. vom Saal, PhD

University of Missouri–Columbia

Speakers

Alicia Bárcena, PhD

University of California, San Francisco

Jeeyeon Cha

Cincinnati Children's Hospital Medical Center

John R. G. Challis, PhD

University of Toronto

Marco Conti, MD

University of California, San Francisco

James Charles Cross, DVM, PhD

University of Calgary

Francesco J. DeMayo, PhD

Baylor College of Medicine

Adrian Erlebacher, MD, PhD

New York University Langone Medical Center

Patricia Hunt, PhD

Washington State University

S. Anath Karumanchi, MD

Beth Israel Deaconess Medical Center

Sarah F. Leibowitz, PhD

The Rockefeller University

Pat R. Levitt, PhD

University of Southern California

Liang Ma, PhD

Washington University

Margaret Ann Miller, PhD

National Center for Toxicological Research, FDA

Kelle H. Moley, MD

Washington University School of Medicine in St. Louis

Louis J. Muglia, MD, PhD

Cincinnati Children's Hospital Medical Center

Bruce Murphy, PhD

Universite de Montreal

Oliver J. Rando, MD, PhD

University of Massachusetts Medical School

R. Michael Roberts, PhD

University of Missouri–Columbia

John M. Rogers, PhD

United States Environmental Protection Agency

Roberto Romero, MD

National Institute of Child Health & Human Development, NIH

John Schimenti, PhD

Cornell University

Thaddeus Schug, PhD

National Institute of Environmental Health Sciences

Michael J. Soares, PhD

Kansas University Medical Center

Jenny Sones, DVM

Cornell University

Martha Susiarjo, PhD

University of Pennsylvania

L. David Wise, PhD

Merck

Sponsors

For sponsorship opportunities please contact Kerstin Hofmeyer, PhD at khofmeyer@nyas.org or 212.298.8610.

Presented by

Academy Friends

Abcam Inc.

Quartzy

Watson Pharmaceuticals, Inc.

Weill Cornell Medical College - The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine

Grant Support

Burroughs Wellcome Fund

Supported in part by March of Dimes Foundation Grant No. 4-FY12-545.

Funding for this conference was made possible (in part) by grant number 1R13ES021699-01 from the National Institute of Environmental Health Sciences (NIEHS) and National Institute on Drug Abuse (NIDA). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Promotional Partners

American College of Medical Genetics and Genomics

Nature

The New York Academy of Medicine

Obstetric-Fetal Pharmacology Research Units (OPRU)

Scientific Research Publishing - Open Journal of Obstetrics and Gynecology

Society for the Study of Reproduction

Abstracts — Day One

Keynote Address

Challenges for Reproductive Toxicology Posed By Unpredicted Effects on Fetuses Of Very Low-Doses Of Estrogenic Endocrine Disrupting Chemicals
Frederick S. vom Saal, PhD, University of Missouri–Columbia

The factors that lead to the disruption of normal fetal development are of great concern. For example, there is evidence that the incidence of prematurity and intrauterine growth restriction (IUGR) is increasing. Significant attention has been devoted to the impact on fetal health of maternal malnutrition in experimental animals (for example, severe protein restriction during pregnancy), although severe malnutrition is not the basis for the increase in prematurity or IUGR in developed countries. There has been less attention paid to the impact of maternal exposure to environmental chemicals on fetal growth and other fetal abnormalities. The chemicals of greatest concern with regard to the disruption of the normal programming of genes that occurs during critical periods in cell differentiation are chemicals that have been found to disrupt hormone action, which are referred to as endocrine disrupting chemicals (EDCs). There is experimental evidence that disruption of the programming of gene expression associated with changes in the epigenome is related to diseases that are expressed at various times in postnatal life (the Developmental Origins of Adult Health and Disease, DOHaD, hypothesis). The concern is that waiting for conclusive evidence from prospective epidemiological studies will lead to generations being exposed to chemicals shown to cause harm in experimental animals. A large number of animal studies show that EDCs disrupt fetal development at very low doses that are below the no adverse effect level (NoAEL) based on the traditional approach currently used in chemical risk assessments by the US-FDA and US-EPA as well as European regulatory agencies (Vandenberg et al, 2012). This traditional approach consists of testing very high doses using very insensitive outcomes to predict effects at the much lower levels of environmental chemicals to which humans are chronically exposed. This approach is flawed in that the core assumption is that all doseresponse relationships are monotonic, and thus effects at high doses predict effects at low doses, which is a false assumption for endogenous hormones and EDCs. In addition, the current approach by regulatory agencies in the initial (Tier 1) screen for the hazards posed by EDCs does not include exposure during development, and thus does not recognize that fetuses, infants and children are not little adults. Specific examples of adverse effects due to exposure to EDCs with estrogenic activity from epidemiological studies and experimental animal research include disruption of metabolic systems involved in obesity, type 2 diabetes and abnormalities in reproductive organs and behavior.
 

Session I: Genetic / Epigenetic Programming of Pre-implantation Development

Networks of RNA Binding Proteins Regulate Maternal mRNA Translation Essential for Oocyte Maturation and Early Embryo Development
Marco Conti, MD, University of California, San Francisco

In the final stages of oocyte maturation, completion of meiotic division is required to generate a haploid genome as well as assemble the molecular machinery responsible for nuclear reprogramming and activation of transcription in the zygote and early embryo. All of these functions rely on a program of translation of maternal mRNAs in the virtual absence of transcription. To define the pattern of protein expression for this critical window in development and to understand the mechanisms governing translational control of the oocyte-to-zygote transition, we have used a genome-wide approach to identify maternal mRNAsrecruited to the polysome fraction and, therefore, actively translated. This analysis has revealed that many of the cellular components necessary for cell cycle progression are finely regulated at the level of translation. Moreover, components that will be used during nuclear reprogramming and early embryo development are synthesized earlier during oocyte maturation and accumulate in the cytoplasm. To investigate the mechanisms underlying selective mRNA translation, the 3′ untranslated region of mRNAs undergoing comparable patterns of recruitment were investigated. This analysis demonstrated that consensus nucleotide sequences recognized by known RNA binding proteins are enriched in mRNAs that are recruited to the polysome during maturation. Knockdown and gain-of-function experiments strongly indicate that a network of RNA binding proteins is coordinating translation or repression of individual maternal mRNAs. This genome-wide approach provides a blueprint of protein expression critical for the oocyte-to-embryo transition.
 
Coauthors: Jing Chen, Matthew Cook, Chih-Jen Lin, Andrej Susor, and Jeong Su Oh, University of California, San Francisco.
 

Maternal Obesity, Oocyte Quality, and Reproductive Outcomes
Kelle H. Moley, MD, Washington University in St. Louis School of Medicine

Approximately 60% of women desiring pregnancy are obese by BMI criterion, with incidence rising exponentially over the last 15 yrs. Unfortunately, maternal obesity is associated with poor outcomes, including increased rates of infertility, pregnancy loss, developmental delay and neurological deficits. From current studies it is not clear if the origin of these problems is attributable to oocyte or embryo development, impaired uterine environment, or a combination of factors. The impact of abnormal metabolic environment on oocyte quality and pregnancy outcomes was initially seen in diabetic mouse models. In animal models of diabetes, oocytes are smaller, and show impaired maturation and increased granulosa cell apoptosis. These findings have been linked to poor reproductive outcomes including growth restriction and congenital anomalies. Similarly in murine models of obesity, exposure to an abnormal endocrine environment impacts the oocyte, the embryo, and pregnancy outcomes. Oocytes from obese mice are significantly smaller show delayed meiotic maturation, and exhibit increased follicular apoptosis. Mice fed a high fat diet have impaired ovulation, fertilization, embryonic development and growth restriction. The inciting metabolic factor is not clear, however, abnormal levels of free fatty acids in follicular fluid as well as sera have been associated with poor oocyte quality and decreased chance of pregnancy in patients undergoing IVF, respectively. Alternatively, these fetal changes, like growth restriction and anomalies, may be due to a combination of oocyte and early preimplantation exposure to free fatty acids as shown in animal models.
 
One proposed mechanism for compromised oocyte quality and poor reproductive outcomes in obese females includes altered mitochondrial activity at the oocyte stage. Abnormal mitochondria structure and function in oocytes from type 1 diabetic mice are associated with poor fertilization rates and abnormal embryo development. It is apparent that both obesity and diabetes influence mitochondrial activity. In obese mice, uneven mitochondrial distribution and altered mitochondrial DNA copy number are linked to impaired embryonic development from the zygote to blastocyst stage. Diabetic mice have increased abnormalities in mitochondria morphology, distribution, and mtDNA copy number. These mice also exhibit spindle defects/chromosome misalignment; defects associated with mitochondrial metabolism and changes in endocrine surroundings. In the unpublished data presented in this talk, we will show that maternal obesity adversely affects oocyte mitochondria and spindle formation, and that this isolated early preimplantation insult will negatively impact embryo outcomes when transferred into nonobese control recipient mice.
 

Trophoblast Cell Subtypes Orchestrating the Development of the Maternal–Fetal Interface
James Charles Cross, DVM, PhD, University of Calgary, Department of Comparative Biology and Experimental Medicine, University of Calgary, Calgary, Canada

The placenta is essential for growth and survival of the fetus during gestation because of both its ability to transport nutrients and oxygen to the fetus but also by producing hormones that promote maternal adaptations to pregnancy. Using the mouse as a model system, my group has identified key regulatory pathways that underlie the development of the placenta and described a complex array of differentiated trophoblast cell types that line the maternal blood spaces in the placenta. In the last few years, we and others have investigated the extent to which the normal development and functions of the placenta can adapt to alterations in the intrauterine environment. Results indicate that: 1) the ability of the placenta to adapt by expansion is limited by the fact that multipotent trophoblast stem cells do not persist beyond embryonic day (E) 8.0; 2) Tissue oxygen levels regulate patterns of trophoblast differentiation, influencing the balance of cell types that form; 3) Prolactin-related hormones from the placenta (the Placental Lactogens) protect the mother against diabetes during pregnancy in part by promoting an increase in the number of her pancreatic beta cells; 4) Expression levels of Placental Lactogens follow feeding patterns in the mother; 5) Specialized cells in the placenta, called glycogen trophoblast cells, can accumulate glucose and they localize both around spiral arteries which bring maternal blood into the placenta as well as small channels that lead maternal blood out of the placenta and into uterine veins. Glycogen content increases during gestational diabetes perhaps buffering against effects of hyperglycemia on the fetus. Together, these results indicate that placenta development and function can be modified by the environment in ways that benefit not just the fetus but also the mother.
 

Session II: Embryo–Uterine Cross-Talk

Paracrine Signals Regulating Embryo Implantation and Uterine Decidualization
Francesco J. DeMayo, PhD, Baylor College of Medicine, Houston

The ability of the uterus to support embryo implantation and pregnancy requires ovarian steroid hormone activation of a network of paracrine signaling between the endometrial epithelium and stroma cells. The identification of the regulatory networks governing uterine physiology has been facilitated by using the mouse as a model and exploiting gene expression and ablation approaches. One critical regulator of uterine physiology is Progesterone. Progesterone signaling through its cognate receptor, the progesterone receptor, PR, regulates uterine development, embryo implantation and the post-implantation support of embryo implantation. Ablation of the PR results in the inability of the uterus to support pregnancy. The PR is expressed in both epithelial and stromal compartments of the endometrium. In order to further define the role of PR action in the uterus, PR was ablated, specifically in the uterine epithelium. This analysis demonstrated that the epithelium is critical in the regulation of the signaling cascades required to activate the pathways that support embryo development and pregnancy. One signaling pathway component regulated by PR is morphogen Indian hedgehog, Ihh. PR acting in the uterine epithelium directly regulates the expression of Ihh in the preimplantation uterine epithelium. Once expressed, Ihh signals to endometrial stroma cells to express, Bone morphogenic protein (BMP), Epidermal Growth Factor (EGF) and Wnt. This in turn activates the signaling pathway to coordinate endometrial stroma, the proliferation, vascularization, and differentiation preparing the stroma of the endometrium for the support of embryo implantation. Ihh and COUP-TFII in the uterus demonstrated that these molecules regulate the window of receptivity in the uterus by coordinating endometrial stroma, proliferation, vascularization and endometrial Estrogen Receptor sensitivity in the uterine epithelium. Understanding the interactions of transcription factors and signaling pathways in the uterus will help determine what processes are required for normal pregnancy and aid in the identification of processes that are altered in infertility and early fetal loss or preterm delivery.
 
Specialized Cooperative Centers in Reproduction and Infertility Research, U54HD0077495 (F.J.D.) and NIH Grant RO1-CA77530 and the Susan G. Komen Award BCTR0503763 (J.P.L.)
 
Coauthor: John P. Lydon, Baylor College of Medicine, Houston.
 

Nuclear Receptor Regulation of Gestation
Bruce Murphy, PhD, Université de Montréal

Nuclear receptors interact with specific regulatory sequences of DNA to modulate gene transcription. The orphan nuclear receptor, liver receptor homolog-1 (Nr5a2) is expressed in the ovary, exclusively in granulosa and luteal cells. Germline deletion in the mouse is lethal during early embryogenesis, requiring tissue-specific disruption of the gene. A Cre/lox strategy employing Cre recombinase driven by the progesterone receptor (genotype PgrCre/+/Nr5a2f/f) deleted Nr5a2 expression from the corpus luteum beginning 4 h after ovulation and completed by 24 h. The effect was abrogation of progesterone synthesis and gestational failure. Embryos were normal and, with progesterone replacement, implanted, but progesterone did not rescue pregnancy. By PCR and immunohistochemistry, Nr5a2 was shown to be expressed the uterine stroma of wild type mice at dpc 3-5, and ablated by dpc 5 in PgrCre/+/Nr5a2f/f mice. Its absence from the uterine stroma resulted in embryo crowding, decidualization failure, and compromised gestation. Embryos displayed substantially reduced size and most pregnancies terminated spontaneously by day 18 of gestation. The ovarian and uterine Nr5a2 deletion resulted in deficiencies of expression of several genes, including Star, Cyp11a1, Hoxa10 and Wnt 4a, among others. Complementary investigations in which Nr5a2 mRNA abundance was reduced in primary cultures of human endometrial stromal cells by siRNA demonstrated a similar abrogation of decidualization, as indicated by cell morphology and reduced marker gene expression. We conclude that NR5A2 plays multiple, non-overlapping roles in reproductive processes, as it is essential for luteal function and placental formation. (Supported by CIHR OGP 10118 to B. Murphy)
 

Immune Surveillance of the Maternal–Fetal Interface: Implications for Fetal Loss and Preterm Birth
Adrian Erlebacher, New York University School of Medicine and New York University Cancer Institute

Successful pregnancy requires delicate control over the maternal immune cells that reside at the maternal/fetal interface. On the one hand, immune cell-mediated inflammation at the maternal/fetal interface is likely to be a major instigator of preterm birth, while immunogenic recognition of fetal/placental antigens by professional antigen presenting cells runs the risk of inducing T cell responses that might directly induce fetal demise. On the other hand, inadequate immune surveillance of the maternal/fetal interface might be expected to increase the risk of ascending infection, or the risk that such infection progresses to chorioamnionitis. We will discuss recent our recent work on the molecular and cellular pathways that regulate immune cell trafficking and homeostasis within the pregnant mouse uterus. Our results demonstrate how the developmental properties of the decidua, i.e. the specialized endometrial stromal tissue that directly encases the implanted embryo, minimize the tissue density of dendritic cells and prevent these cells from surveying the placenta for antigens. We will also discuss how the decidua regulates macrophage population dynamics to minimize macrophage densities. Since dendritic cells are key instigators of immunogenic T cell responses while macrophages are major promoters of tissue inflammation, these results have major implications for the immunology of pregnancy its complications.
 
Coauthors: Elisa Tagliani, Mary K. Collins, and Patrice Nancy, New York University School of Medicine.
 

Session III: Young Investigator Presentations

Asynchronous Peri-implantation Events Characterize a Mouse Model of Preeclampsia, bph/5
Jenny Sones, DVM, Cornell University, Ithaca, NY

Preeclampsia (PE), a pregnancy-specific disorder characterized by a sudden late gestational rise in blood pressure and urinary protein levels, is one of the leading causes of perinatal and maternal morbidity and mortality. Our lab discovered an inbred mouse strain (BPH/5) that spontaneously develops these cardinal signs of PE during pregnancy, along with early placental defects, decreased litter size, and low-birth-weight pups. Although abnormal placentation in early gestation is thought to be responsible for the cascade of events leading to the clinical syndrome of PE, the precise mechanisms are still not clear. Proper placental development begins with synchronous implantation of an activated blastocyst into the receptive uterus. We hypothesized that defects in the implantation process would be observed in the BPH/5 model of PE. BPH/5 mice exhibit a delay in timing of implantation as well as embryo clustering. BPH/5 pregnant females also show aberrant ovarian hormone profiles leading up to and during implantation, and BPH/5 embryos demonstrate abnormal maturation kinetics as compared to C57 controls. Gene expression patterns of the implantation signaling molecules Lif, Hb-egf, and Cox-2 are dysregulated in BPH/5 implantation sites and suggest delayed uterine receptivity and decidualization. Taken together, our data suggest that BPH/5 mice have dysregulated implantation, which is associated with both delayed blastocyst development and inadequate uterine receptivity. The role of asynchronous embryo-uterine cross-talk in the pathogenesis of PE in BPH/5 is the subject of ongoing investigations.
 

Coauthors: Yi Zhou, PhD,1 Ashley Woods, PhD,1 Emilie Williamson,1 Ethan Green,1 Catherine Isroff,1 Robin L Davisson, PhD,1,2
1Cornell University, Ithaca, NY
2Weill Cornell Medical College, New York, NY

Heightened Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling Provokes Premature Decidual Senescence and Preterm Birth
Jeeyeon Cha, Division of Reproductive Sciences, Cincinnati Children's Hospital Research Center, Cincinnati, OH, USA

p53, a tumor suppressor encoded by Trp53, is strongly associated with cancer and has diverse physiological functions. However, its role in reproduction is poorly understood. Female mice harboring a uterine deletion of Trp53 (p53d/d) show normal ovulation, fertilization and implantation; but post-implantation decidual cells (day 8 of pregnancy) show increased terminal differentiation and senescenceassociated growth restriction. Interestingly, p53d/d females show increased incidence of preterm birth without decreases in serum progesterone levels, mimicking aspects of human parturition. This condition is associated with increased levels of uterine Cox2 and PGF2α. Preterm birth is rescued in these mice by an oral gavage of Cox2 inhibitor late in pregnancy, suggesting that PGF2α generated by Cox2 is involved. More strikingly, we now have evidence that decidual senescence in p53d/d females is reflected in increased mTORC1 signaling and a low dose of mTORC1 inhibitor rapamycin given early in pregnancy attenuates the senescence phenotype and rescues preterm birth. Collectively, this study shows for the first time that progressive decidual senescence approaching term birth is a normal phenomenon, and that premature decidual senescence early in pregnancy leads to preterm birth in mice. This study constitutes an unanticipated role of mTORC1 in preterm birth upstream of Cox2, suggesting that the mTORC1-Cox2 signaling axis is critical in timing of birth since targeting either of these players rescues preterm birth. These preclinical studies may help to elucidate the mechanism of human birth and develop new strategies to combat this global problem.
 

Coauthors: Yasushi Hirota2, Takiko Daikoku1, Sudhansu K. Dey1
1Division of Reproductive Sciences, Cincinnati Children's Hospital Research Center, Cincinnati, OH, USA
2Department of Obstetrics and Gynecology, University of Tokyo, Tokyo, Japan


Extraembryonic Hematopoietic Niches: Cross-Talk Between Non-Hematopoietic and Hematopoietic Populations in Human Placenta and Chorion
Alicia Bárcena, PhD, The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research Center for Reproductive Sciences, Department of Obstetrics, Gynecology & Reproductive Sciences University of California, San Francisco, San Francisco, CA

Hematopoietic progenitors and hematopoietic stem cells (HSCs) expressing CD34 and CD45 antigens are present in the placenta and chorion from 5 to 40 weeks of gestation. However, fully functional HSCs — defined by their ability to produce long-term and multilineage reconstitution when transplanted into immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice — only manifest in these extraembryonic tissues from the 15th week of gestation onward. Therefore, extraembryonic progenitors/HSCs become functionally mature when their density declines from a peak at 5-8 weeks. The switch that extraembryonic HSCs undergo at 15th week may reflect the immature nature of these cells earlier in ontogeny and could be due to signals delivered by their niche. Immunolocalization experiments of CD34++CD45+ cells show that these cells reside in the vicinity of trophoblast progenitors cells (TBPCs) and interact with stromal cells in the chorion, and with endothelial cells in the placenta. To study the contribution of the niche’s different components on regulating hematopoesis, we performed co-culture experiments in the presence of mesenchymal stromal cell lines derived from placenta and chorion, and TBPCs derived from chorion. We conclude that both mesenchymal stromal cells and TBPCs regulate the hematopoietic potential of extraembryonic and intraembryonic HSCs. In addition, we investigated the expression of chemokine receptors, cytokine receptors and adhesion molecules on extraembryonic HSCs to assess whether the expression of these molecules changes during development. We have thus established a new culture system that could be applied to investigate the cells and molecules involved in the funtional regulation of HSCs during development.
 

Coauthors: Marcus O. Muench, Mirhan Kapidzic, Nicholas Larocque, Susan J. Fisher, The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research Center for Reproductive Sciences, Department of Obstetrics, Gynecology & Reproductive Sciences University of California, San Francisco, San Francisco, CA


Effects of Bisphenol a Exposure on Genomic Imprinting in Mouse
Martha Susiarjo, PhD, Center of Excellence in Environmental Toxicology and Department of Cell and Developmental Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Exposure to the common compound bisphenol A (BPA) is linked to developmental abnormalities in model organisms and humans. The molecular mechanisms, however, are unclear and elucidating these pathways will provide insight into the windows of vulnerability and preventive measures. Recently, BPA has been shown to alter DNA methylation in rodents, proposing that epigenetic mechanisms may be relevant. We investigated effects of exposure onimprinted genes in the mouse. Imprinted genes are subject to differential DNA methylation and they regulate fetal, placental and postnatal development. Perturbed imprinting is linked to diseases including the Beckwith Wiedemann, Prader Williand Angelman Syndromes. We exposed pregnant mice to BPA and analyzed their offspring a tE9.5. Using real time PCR, we found that exposure disrupted expression of genes relevant to imprinting diseases, including the Snrpn, Ube3a, Igf2, Kcnq1ot1 and Cdkn1c genes. Furthermore, we observed tissue-specific effects with most genes affected in the placenta. Our bisulfite sequencing and pyrosequencing data demonstrated that gene transcription changes were associated with altered methylation at differentially methylated regions. Additionally, Luminometric Methylation Assay studies showed that exposure reduced global methylation in the placenta, but not the embryo. Histology revealed that BPA-exposed placentas were larger with expanded junctional zone but smaller labyrinth, and had increased accumulation of red blood cells. As the placenta influences embryonic growth and development, our data suggest that BPA-induced perturbed genomic imprinting candisrupt fetal and postnatal health. In the future, we will conduct genome wide methylation and expression studies to link altered epigenetic signatures to expression changes.
 
Research supported by University of Pennsylvania Center of Excellence in Environmental Toxicology 2008 Pilot Project Funding P30 ES013508 and NIEHS F32ES019416.
 

Coauthors: Isaac Sasson, Department of Obstetric and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Clementina Mesaros, Center of Excellence in Environmental Toxicology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Marisa Bartolomei, Center of Excellence in Environmental Toxicology and Department of Cell and Developmental Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA


Travel & Lodging

Our Location

The New York Academy of Sciences

7 World Trade Center
250 Greenwich Street, 40th floor
New York, NY 10007-2157
212.298.8600

Directions to the Academy

Hotels Near 7 World Trade Center

Recommended partner hotel

Club Quarters, World Trade Center
140 Washington Street
New York, NY 10006
Phone: 212.577.1133

The New York Academy of Sciences is a member of the Club Quarters network, which offers significant savings on hotel reservations to member organizations. Located opposite Memorial Plaza on the south side of the World Trade Center, Club Quarters, World Trade Center is just a short walk to the Academy.

Use Club Quarters Reservation Password NYAS to reserve your discounted accommodations online.

Other nearby hotels

Millenium Hilton

212.693.2001

Marriott Financial Center

212.385.4900

Club Quarters, Wall Street

212.269.6400

Eurostars Wall Street Hotel

212.742.0003

Gild Hall, Financial District

212.232.7700

Wall Street Inn

212.747.1500

Ritz-Carlton New York, Battery Park

212.344.0800

Special Needs and Additional Information

For any additional information and for special needs, including child/family care resources available to conference attendees, please email cocampo@nyas.org or call Crystal Ocampo at 212.298.8632.